EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tryp Therapeutics's enterprise value is €5.96 Mil.
Tryp Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Nov. 2023 was €-2.75 Mil. Therefore, Tryp Therapeutics's EV-to-EBITDA for today is -2.17.
The historical rank and industry rank for Tryp Therapeutics's EV-to-EBITDA or its related term are showing as below:
STU:8FW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -102.23 Med: 0 Max: 0
Current: -2.17
STU:8FW's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.385
vs STU:8FW: -2.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Tryp Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Tryp Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tryp Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Tryp Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tryp Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tryp Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tryp Therapeutics's EV-to-EBITDA falls into.
Tryp Therapeutics's current Enterprise Value is €5.96 Mil.
Tryp Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tryp Therapeutics's PE Ratio for today is calculated as:
Tryp Therapeutics's share price for today is €0.0355.
Tryp Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Tryp Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Tryp Therapeutics Inc is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, for the treatment of diseases with unmet medical needs. Tryp's program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The company operates in two reportable segments; the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:8FW has been successfully added to your 